

Mary E Keir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2699821/publications.pdf>

Version: 2024-02-01

37
papers

10,230
citations

201674

27
h-index

330143

37
g-index

38
all docs

38
docs citations

38
times ranked

14984
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 2008, 26, 677-704.	21.8	4,462
2	Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses. Immunity, 2007, 27, 111-122.	14.3	1,464
3	Tissue expression of PD-L1 mediates peripheral T cell tolerance. Journal of Experimental Medicine, 2006, 203, 883-895.	8.5	1,042
4	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet, The, 2014, 384, 309-318.	13.7	421
5	PD-1 and its ligands in T-cell immunity. Current Opinion in Immunology, 2007, 19, 309-314.	5.5	388
6	Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8 ⁺ T-Cell-Mediated Injury in the Heart. Circulation, 2007, 116, 2062-2071.	1.6	221
7	The role of IL-22 in intestinal health and disease. Journal of Experimental Medicine, 2020, 217, e20192195.	8.5	217
8	PD-1 Regulates Self-Reactive CD8 ⁺ T Cell Responses to Antigen in Lymph Nodes and Tissues. Journal of Immunology, 2007, 179, 5064-5070.	0.8	212
9	The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo. Journal of Immunology, 2011, 187, 1097-1105.	0.8	159
10	A randomised phase I study of etrolizumab (rhuMab $\hat{I}27$) in moderate to severe ulcerative colitis. Gut, 2013, 62, 1122-1130.	12.1	134
11	Association Between Response to Etrolizumab and Expression of Integrin $\hat{I}E$ and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology, 2016, 150, 477-487.e9.	1.3	133
12	The B7/CD28 costimulatory family in autoimmunity. Immunological Reviews, 2005, 204, 128-143.	6.0	129
13	PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. Journal of Clinical Investigation, 2010, 120, 2508-2515.	8.2	129
14	Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes. Journal of Immunology, 2005, 175, 7372-7379.	0.8	122
15	Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut, 2017, 66, 2063-2068.	12.1	104
16	Selective autophagy of the adaptor TRIF regulates innate inflammatory signaling. Nature Immunology, 2018, 19, 246-254.	14.5	99
17	EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. American Journal of Gastroenterology, 2013, 108, 1891-1900.	0.4	97
18	IFN- \hat{I} Secretion by Type 2 Predendritic Cells Up-Regulates MHC Class I in the HIV-1-Infected Thymus. Journal of Immunology, 2002, 168, 325-331.	0.8	87

#	ARTICLE	IF	CITATIONS
19	Programmed Death 1 Ligand (PD-L) 1 and PD-L2 Limit Autoimmune Kidney Disease: Distinct Roles. <i>Journal of Immunology</i> , 2007, 179, 7466-7477.	0.8	73
20	Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. <i>Nature Medicine</i> , 2022, 28, 766-779.	30.7	70
21	The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. <i>Medicinal Research Reviews</i> , 2020, 40, 245-262.	10.5	60
22	Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S653-S668.	1.3	56
23	CD28 Costimulation Regulates Genome-Wide Effects on Alternative Splicing. <i>PLoS ONE</i> , 2012, 7, e40032.	2.5	51
24	Î±EÎ²7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw189.	1.3	43
25	IFN-Î±-Induced Upregulation of CCR5 Leads to Expanded HIV Tropism In Vivo. <i>PLoS Pathogens</i> , 2010, 6, e1000766.	4.7	42
26	Generation of CD3+CD8low Thymocytes in the HIV Type 1-Infected Thymus. <i>Journal of Immunology</i> , 2002, 169, 2788-2796.	0.8	40
27	A Membrane-bound Fas Decoy Receptor Expressed by Human Thymocytes. <i>Journal of Biological Chemistry</i> , 2000, 275, 7988-7993.	3.4	38
28	Regulation and Role of Î±E Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease. <i>Journal of Immunology</i> , 2021, 207, 2245-2254.	0.8	29
29	Dual targeting of lymphocyte homing and retention through Î±4Î²7 and Î±EÎ²7 inhibition in inflammatory bowel disease. <i>Cell Reports Medicine</i> , 2021, 2, 100381.	6.5	24
30	Stratified medicine in inflammatory disorders: From theory to practice. <i>Clinical Immunology</i> , 2015, 161, 11-22.	3.2	21
31	Functional Consequences of the Macrophage Stimulating Protein 689C Inflammatory Bowel Disease Risk Allele. <i>PLoS ONE</i> , 2013, 8, e83958.	2.5	17
32	AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1191-1199.	1.3	14
33	T Lymphocytes Expressing AlphaE Beta7 Integrin in Ulcerative Colitis: Associations With Cellular Lineage and Phenotype. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1504-1505.	1.3	11
34	Bridging Toll-like- and B Cell-Receptor Signaling: Meet Me at the Autophagosome. <i>Immunity</i> , 2008, 28, 729-731.	14.3	10
35	Inflammatory Bowel Disease Susceptibility Gene <i>C1ORF106</i> Regulates Intestinal Epithelial Permeability. <i>ImmunoHorizons</i> , 2018, 2, 164-171.	1.8	8
36	Anti-CD3 mAb treatment cures PDL1 ^{hi} .NOD mice of diabetes but precipitates fatal myocarditis. <i>Clinical Immunology</i> , 2011, 140, 47-53.	3.2	2

#	ARTICLE	IF	CITATIONS
37	The Importance of Molecular Immune Investigation in Therapeutic Clinical Development for Biomarker Assessment. Journal of Crohn's and Colitis, 2019, 13, 956-957.	1.3	0